Literature DB >> 18032691

Early events in the recognition of danger signals after tissue injury.

David J Kaczorowski1, Kevin P Mollen, Rebecca Edmonds, Timothy R Billiar.   

Abstract

The systemic inflammatory response observed in the setting of overwhelming infection bears striking similarities to that observed in the setting of severe traumatic injury from a clinical and physiologic standpoint. Recent observations have demonstrated that these disparate clinical entities share common mediators on a molecular level. TLRs, specifically TLR4, and the endogenous molecule high-mobility group box 1 are among the mediators that are known to play a role in inflammation in the setting of sepsis. Evidence is accumulating that demonstrates that these mediators also play a role in the host response to tissue injury. Here, we highlight findings from the 7th World Conference on Trauma, Shock, Inflammation and Sepsis in Munich, Germany, in the context of this growing body of literature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18032691     DOI: 10.1189/jlb.0607374

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  62 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

2.  Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms.

Authors:  E Wang; Yan Feng; Ming Zhang; Lin Zou; Yan Li; Emmanuel S Buys; Peigen Huang; Peter Brouckaert; Wei Chao
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

3.  Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury.

Authors:  Jamie C Zampell; Sonia Elhadad; Tomer Avraham; Evan Weitman; Seth Aschen; Alan Yan; Babak J Mehrara
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

4.  Pivotal advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms.

Authors:  David J Kaczorowski; Amin Afrazi; Melanie J Scott; Joon H Kwak; Roop Gill; Rebecca D Edmonds; Yujian Liu; Jie Fan; Timothy R Billiar
Journal:  J Leukoc Biol       Date:  2010-04-22       Impact factor: 4.962

Review 5.  Epigenetic regulation of immune cell functions during post-septic immunosuppression.

Authors:  William F Carson; Karen A Cavassani; Yali Dou; Steven L Kunkel
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

6.  Reduced photoreceptor death and improved retinal function during retinal degeneration in mice lacking innate immunity adaptor protein MyD88.

Authors:  Sarah Syeda; Amit K Patel; Tinthu Lee; Abigail S Hackam
Journal:  Exp Neurol       Date:  2015-02-25       Impact factor: 5.330

7.  Impact of intestinal ischemia/reperfusion and lymph drainage on distant organs in rats.

Authors:  Gui-Zhen He; Kai-Guo Zhou; Rui Zhang; Yu-Kang Wang; Xue-Feng Chen
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

8.  Lrg participates in lipopolysaccharide preconditioning-induced brain ischemia injury via TLR4 signaling pathway.

Authors:  Gu Gong; Shurong Bai; Wei Wu; Ling Hu; Yinghai Liu; Jie Niu; Xuemei Dai; Liang Yin; Xiaowu Wang
Journal:  J Mol Neurosci       Date:  2014-02-15       Impact factor: 3.444

9.  Translational systems biology of inflammation and healing.

Authors:  Yoram Vodovotz
Journal:  Wound Repair Regen       Date:  2010 Jan-Feb       Impact factor: 3.617

Review 10.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.